CT-322 in Treating Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma

Phase 1 Completed 40 enrolled Adnexus, A Bristol-Myers Squibb R&D Company

Non-randomizedSingle-groupOpen-labelTreatment

Summary

RATIONALE: CT-322 may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the cancer. PURPOSE: This phase I trial is studying the side effects of CT-322 in treating patients with advanced solid tumors or non-Hodgkin's lymphoma.

Timeline

Start: 2006-08
Primary completion: 2008-11
Completion: 2009-02

Publications

Tolcher AW, Sweeney CJ, Papadopoulos K, Patnaik A, Chiorean EG, Mita AC, Sankhala K, Furfine E, Gokemeijer J, Iacono L, Eaton C, Silver BA, Mita M. Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin. Clin Cancer Res. 2011 Jan 15;17(2):363-71. doi: 10.1158/1078-0432.CCR-10-1411. Epub 2011 Jan 11.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PEGDINETANIB	Protein / enzyme biologic	0.1 mg/kg	Intravenous
Subject	PEGDINETANIB	Protein / enzyme biologic	2 mg/kg	Intravenous
Subject	PEGDINETANIB	Protein / enzyme biologic	3 mg/kg	Intravenous

CT-322 in Treating Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma

Summary

Timeline

Publications

Drugs

Indications